Product is now available exclusively through Anovo specialty pharmacy Product is stable at room temperature while Carbaglu® requires refrigeration Eton Cares patient support program will offer $0 co-pays to commercial insurance patients DEER PARK, Ill. , Dec.

DEER PARK, Ill. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the third quarter ended September 30, 2021 .

- Tolmar’s 62-person sales force will co-promote ALKINDI SPRINKLE® to pediatric endocrinologists - DEER PARK, Ill. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that it has entered into a multi-year agreement with Tolmar Pharmaceuticals, Inc.

The first and only FDA-approved ready-to-use liquid topiramate DEER PARK, Ill. and WOBURN, Mass. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON) and Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EPRONTIA™

DEER PARK, Ill. , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2021 financial and operating results on

-Product is the first generic alternative to one of the highest priced pharmaceutical products in the world DEER PARK, Ill. , Oct. 28, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for

DEER PARK, Ill. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2021 .

DEER PARK, Ill. , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2021 financial and operating results on

Expands Eton’s Adrenal Insufficiency Orphan Drug Portfolio ZENEO® Hydrocortisone is Expected to be the First and Only Hydrocortisone Autoinjector for Patients Requiring Emergency Hydrocortisone Proprietary ZENEO® Needleless Device is Covered by 24 U.S.

DEER PARK, Ill. , June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres ® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of